Defibrotide in the treatment of hepatic veno-occlusive disease

Long-awaited news for hepatic veno-occlusive disease.

In this issue of Blood, Palomo et al provide new insight into the mechanism of action of defibrotide as an endothelial protective agent, while Richardson et al present the encouraging final results of the phase 3 clinical study of defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in day +100 survival after hematopoietic cell transplantation ...

CASE STUDY Pulmonary veno-occlusive disease in myeloproliferative disorder

The present study reports a case of biopsy-proven pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a patient suffering from a chronic myeloproliferative disorder. The pulmonary disease evolved favourably under treatment with defibrotide, a pro-fibrinolytic medication used in hepatic veno-occlusive disease.

Defibrotide for Prevention and Treatment of Veno-Occlusive Disease in Adults: Single-Center Experience

Background: Hepatic veno-occlusive disease (VOD) has been reported at a rate up to 50% following intensive conditioning regimens used in allogeneic hematopoietic stem cell transplantation (AHSCT). Studies on the prophylactic effect of defibrotide to prevent hepatic VOD in adults are rare. Purpose: The research presented here aimed to evaluate whether propylactic defibrotide use can reduce incid...

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, is a potentially life-threatening complication of chemotherapeutic conditioning used in preparation for hematopoietic stem-cell transplantation (SCT). VOD may occur in up to 62% of patients undergoing SCT, with onset generally within the first month after SCT. In severe cases, 100-day mortality is in excess of ...

Defibrotide in Veno-Occlusive Disease in Public Hospitals of Paris: Funding Issues and Perspectives.

In hematopoietic stem cell transplantation, veno-occlusive disease (VOD) is a major complication associated with high mortality rates (90%) in which defibrotide is the first line treatment. In 2014, this treatment received a market authorization (MA) only in curative treatment of severe VOD. In France, a temporary authorization for use was attributed to defibrotide for preventive treatment of V...

Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.